Cypherpunk Technologies Inc. (CYPH)
NASDAQ
Closed
Aug 24, 2026
Day's Range
1.5352 wk Range
0.2700Overview - CYPH - Cypherpunk Technologies Inc.
Key Statistics
Valuation
Enterprise Value
145.43M
P/E (Trailing)
‪2.21‬
P/E (Forward)
‪-15.77‬
PEG Ratio
‪0.09‬
Price / Book
‪1.09‬
EV / EBITDA
‪-4.06‬
Profitability
Profit Margin
‪0.00%‬
Operating Margin
‪0.00%‬
Return on Assets
‪-13.79%‬
Return on Equity
‪-1.20%‬
Ownership
Shares Outstanding
93.92M
Float
75.06M
Short % of Shares Outstanding
‪8.56%‬
Held by Insiders
‪8.33%‬
Held by Institutions
‪36.68%‬
Price stats
Beta
‪0.06‬
50-Day Avg
‪0.7126‬
200-Day Avg
‪0.9346‬
Dividends
Payout Ratio
‪0.00%‬
Analyst Consensus
1 analysts
Shariah Compliance
Report Date: Feb 20, 2025
Screened by Zoya using the AAOIFI methodology.
Market Cap - CYPH - Cypherpunk Technologies Inc.
Peers - CYPH - Cypherpunk Technologies Inc.
Peer Comparison
Compared with companies in Asset Management listed on NASDAQ.
- CYPHNASDAQCypherpunk Technologies Inc.153.02MMarket Cap+82.39%52-week change2.22P/E (Trailing)‪0.00%‬Profit Margin
- CGNASDAQThe Carlyle Group Inc.17.59BMarket Cap-28.96%52-week change51.43P/E (Trailing)‪13.01%‬Profit Margin
- ARCCNASDAQAres Capital Corporation14.30BMarket Cap-10.84%52-week change14.87P/E (Trailing)‪30.90%‬Profit Margin
- FSVNASDAQFirstService Corporation6.34BMarket Cap-37.37%52-week change40.93P/E (Trailing)‪2.88%‬Profit Margin
- FANASDAQFirst Advantage Corporation3.58BMarket Cap+20.24%52-week change139.33P/E (Trailing)‪1.51%‬Profit Margin
- GBDCNASDAQGolub Capital BDC, Inc.3.42BMarket Cap-10.73%52-week change20.00P/E (Trailing)‪21.45%‬Profit Margin
- CSQNASDAQCalamos Strategic Total Return Fund3.32BMarket Cap+11.04%52-week change3.14P/E (Trailing)‪1,347.78%‬Profit Margin
Profile Summary - CYPH - Cypherpunk Technologies Inc.
About
Cypherpunk Technologies Inc. is a biopharmaceutical company focused on developing novel antibody therapies for cancer treatment, with a strategic emphasis on biomarker-targeted approaches. The company’s lead clinical-stage candidate, DKN-01, is a monoclonal antibody designed to inhibit Dickkopf-related protein 1 and…
The information on this page is provided for general informational purposes only and is not investment advice.
Market data provided by Twelve Data. Shariah compliance data provided by Zoya. Charting by TradingView.
Last updated:
